Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (293)	1/7/2003 7:55:16 PM
From: Icebrg	Read Replies (1) \| Respond to of 897

>>One is AN-1792, Elan's Alzheimer's immunotherapy that caused CNS inflammation in some patients. Development is not halted, at least not yet, but that one is dead in the water until they can find a way around that problem (say a subset). Not likely this year, if ever.>> Elan has by no means given up yet. According to Dr. Tracy, Dale Schenk seems to have indicated that Elan is aiming to move another four (4!) Alzheimer's agents into the clinic this year. Of which Dr. Tracy is guessing that two will be back-up vaccines (and the other two beta-secretase inhibitors). That will most probably not have much effect on AGEN's overall revenue picture, but I though at least I should mention it. Erik